<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00638508</url>
  </required_header>
  <id_info>
    <org_study_id>06/07/VA3</org_study_id>
    <nct_id>NCT00638508</nct_id>
  </id_info>
  <brief_title>ON-Q Pump Infusion of Ketorolac and Ropivacaine at the Wound Site for Postoperative Pain Management</brief_title>
  <official_title>The Analgesic Efficacy of Continuous Infusion of Ketorolac and Ropivacaine at the Wound Site Using ON-Q Pump for Postoperative Pain Management</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maimonides Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>I-Flow</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Maimonides Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      After surgery it is normal to experience some pain at the site of operation. In order to
      reduce the pain, medication such as Morphine is injected into a vein using a Patient
      Controlled Analgesia (PCA) pump that is kept at bed side, and is activated by the patient
      when needed. However, Morphine is an opioid drug, which can cause side effects such as
      sedation, nausea, vomiting, and reduced breathing on prolonged use. In addition to the opioid
      drugs, local anesthetics, and other drugs called Non steroidal anti inflammatory drugs
      (NSAIDs) have been injected locally to provide prolonged pain relief without the side effects
      of morphine. Recently a portable device called ON-Q pump has been developed to continuously
      infuse the local anesthetic through 2 small catheters inserted at the wound site. The ON-Q
      Pump is a small tennis ball sized unit made of a soft synthetic material that slowly infuses
      the drug through the catheters by elastic force. This pump is very safe and is attached to a
      bedside pole or the patient's hospital gown. This pump has already been approved by the FDA
      for clinical use, and has been reported to provide effective pain management after some
      surgical procedures.

      The primary aim of the present study is to evaluate the relative efficacy of the drugs
      Ketorolac and Ropivacaine infused through the ON-Q pump in reducing the pain following
      gynecologic surgery. Ketorolac and Ropivacaine are approved drugs that are frequently used
      for post operative pain relief. Our hypothesis is that these two drugs in combination will
      provide better analgesia than Ketorolac alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study would include a total of 60 patients randomized into 2 equal groups. Patients will
      be interviewed in the holding area and informed signed consent will be obtained. Patients
      will be induced with general anesthesia in keeping with standard practice. At the end of
      surgical procedure, before the patient is extubated, the Surgeon will secure the 2 catheters
      of the ON-Q pump at two levels of the fascia near the incision site. First the surgeon will
      instill at the wound site a bolus dose of 30 ml of 0.9% saline with 10 mg Ketorolac in Group
      I, or 30 ml of saline with 0.5% Ropivacaine and 10 mg Ketorolac in Group II patients. Then
      the continuous infusion with the ON-Q pump will be started at 4 ml/hr, and Group I patients
      will receive saline with Ketorolac at 5 mg/hr not to exceed 120 mg per day, and Group II will
      receive saline with 0.5% Ropivacaine plus Ketorolac at 5 mg/hr. Patients will be extubated,
      as per standard anesthetic practice. All patients will receive anti ulcer medication. On
      arrival at the Post Anesthesia Care Unit (PACU), the patient will receive an i.v. PCA pump,
      which will administer Morphine Sulfate 2 mg in incremental doses on demand by the patient.

      A blinded investigator will collect the study data from each patient at 6, 12, 24, and 48 hrs
      postoperative periods. The data collected would include 1) Visual Analog Scale (VAS) scores
      for pain at rest, on coughing and on moving, 2) PCA demands by the patient and actual
      deliveries of morphine, 3) &quot;rescue&quot; analgesic requirements (for pain score of 4 or greater).
      4) VAS scores for Nausea, drowsiness, and satisfaction, and 5) number of vomiting.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Scores at Rest</measure>
    <time_frame>1 hour after the surgery</time_frame>
    <description>Patients report pain scores at rest using Visual Analog Scale (VAS). This scale measures the severity of pain and ranges from from 1-10, &quot;1&quot; being minimal pain intensity and &quot;10&quot; being maximal pain intensity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain Score at Rest</measure>
    <time_frame>At the end of 6 hours after surgery</time_frame>
    <description>Patients report pain scores at rest using Visual Analog Scale (VAS). This scale measures the severity of pain and ranges from 1-10, &quot;1&quot; being minimal pain intensity and &quot;10&quot; being maximal pain intensity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain Scores at Rest</measure>
    <time_frame>48 hours after surgery</time_frame>
    <description>Pain scores at rest were measured using the Visual Analog Scale (VAS) at the end of 48 hours. This scale measures the severity of pain and ranges from 1-10, &quot;1&quot; being minimal pain intensity and &quot;10&quot; being maximal pain intensity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain Score on Coughing</measure>
    <time_frame>1 hour after the surgery</time_frame>
    <description>Pain scores on coughing were measured using the Visual Analog Scale (VAS) at the end of 48 hours. This scale measures the severity of pain and ranges from 1-10, &quot;1&quot; being minimal pain intensity and &quot;10&quot; being maximal pain intensity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain Scores on Coughing</measure>
    <time_frame>6 hours after surgery</time_frame>
    <description>Pain scores on coughing were measured using the Visual Analog Scale (VAS) at the end of 6 hours after surgery. This scale measures the severity of pain and ranges from 1-10, &quot;1&quot; being minimal pain intensity and &quot;10&quot; being maximal pain intensity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain Scores on Coughing</measure>
    <time_frame>48 hours after surgery</time_frame>
    <description>Pain scores on coughing were measured using the Visual Analog Scale (VAS). This scale measures the severity of pain and ranges from 1-10, &quot;1&quot; being minimal pain intensity and &quot;10&quot; being maximal pain intensity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain on Movement</measure>
    <time_frame>1 hour after surgery</time_frame>
    <description>Pain scores on movement was assessed using the Visual Analog Scale (VAS). This scale measures the severity of pain and ranges from 1-10, &quot;1&quot; being minimal pain intensity and &quot;10&quot; being maximal pain intensity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain Scores on Movement</measure>
    <time_frame>6 hours after surgery</time_frame>
    <description>Pain scores on movement were assessed using the Visual Analog Scale (VAS) at the end of 6 hours. This scale measures the severity of pain and ranges from 1-10, &quot;1&quot; being minimal pain intensity and &quot;10&quot; being maximal pain intensity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain on Movement</measure>
    <time_frame>48 hours afetr surgery</time_frame>
    <description>Pain scores on movement were measured 48 hours after surgery using the Visual Analog Scale (VAS). This scale measures the severity of pain and ranges from 1-10, &quot;1&quot; being minimal pain intensity and &quot;10&quot; being maximal pain intensity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Morphine Equivalents Utilization</measure>
    <time_frame>1 hour after surgery</time_frame>
    <description>Utilization of morphine and morpine equivalents for rescue analgesia was reviewed and calculated in milligrams.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morphine Equivalents</measure>
    <time_frame>12 hours after surgery</time_frame>
    <description>Utilization of morphine and morphine equivalents for rescue analgesia was reviewed and calculated in milligrams.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morphine Equivalents</measure>
    <time_frame>48 hours afetr surgery</time_frame>
    <description>Utilization of morphine and morphine equivalents for rescue analgesia, was reviewed and calculated in milligrams.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DROWSINESS</measure>
    <time_frame>1 hour after surgery</time_frame>
    <description>The severity of drowsiness was measured using Visual Analog Scale (VAS). The VAS scale ranges from 1-10, &quot;1&quot; meaning minimally drowsy and &quot;10&quot; meaning maximally drowsy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DROWSINESS</measure>
    <time_frame>48 hours</time_frame>
    <description>The severity of drowsiness was measured using Visual Analog Scale (VAS). The VAS scale ranges from 1-10, &quot;1&quot; meaning minimally drowsy and &quot;10&quot; meaning maximally drowsy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NAUSEA</measure>
    <time_frame>1 hour after surgery</time_frame>
    <description>The severity of nausea was measured using Visual Analog Scale (VAS). The VAS scale ranges from 1-10, &quot;1&quot; meaning minimally nauseous and &quot;10&quot; meaning maximally nauseous.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NAUSEA</measure>
    <time_frame>48 hours</time_frame>
    <description>The severity of nausea was measured using Visual Analog Scale (VAS). The VAS scale ranges from 1-10, &quot;1&quot; meaning minimally nauseous and &quot;10&quot; meaning maximally nauseous.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VOMITING</measure>
    <time_frame>6 hours after surgery</time_frame>
    <description>Data on number of episodes of vomiting was obtained, 6 hours after the surgery. The number of episodes were reported in numerical values, the lower numbers indicating fewer episodes and the higher numbers indicating more number of episodes of vomiting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VOMITING</measure>
    <time_frame>12 hours</time_frame>
    <description>Data on number of episodes of vomiting was obtained, 12 hours after the surgery. The number of episodes were reported in numerical values, the lower numbers indicating fewer episodes and the higher numbers indicating more number of episodes of vomiting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PATIENT SATISFACTION</measure>
    <time_frame>1 hour after surgery</time_frame>
    <description>Patient's overall satisfaction was measured using Visual Analog Scale (VAS). This scale ranges from 1-10, &quot;1&quot; indicating least satisfied and &quot;10&quot; indication very well satisfied.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PATIENT SATISFACTION</measure>
    <time_frame>48 hours afetr surgery</time_frame>
    <description>Patient's overall satisfaction was measured using Visual Analog Scale (VAS). This scale ranges from 1-10, &quot;1&quot; indicating least satisfied and &quot;10&quot; indication very well satisfied.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">67</enrollment>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>Ketorolac</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive Ketorolac at 5 mg/hr not to exceed 120 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketorolac with Ropivacaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive Ketorolac 5 mg and Ropivacaine 0.5% (Group 2) via an infusion catheter at the incision site</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac</intervention_name>
    <description>Patients will receive Ketorolac at 5 mg/hr not to exceed 120 mg/day</description>
    <arm_group_label>Ketorolac</arm_group_label>
    <other_name>Toradol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac and Ropivacaine</intervention_name>
    <description>Patients will receive Ketorolac at 5 mg/hr plus 0.5% Ropivacaine</description>
    <arm_group_label>Ketorolac with Ropivacaine</arm_group_label>
    <other_name>Toradol and Naropin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients belonging to ASA class I to II classification who are undergoing abdominal
             gynecologic surgery will be included in the study.

        Exclusion Criteria:

          -  Patients who are allergic to NSAIDs, Asthmatics, and those who have peptic ulcer,
             sepsis, or coagulation problems will be excluded from the study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kalpana Tyagaraj, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maimonides Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maimonides Medical Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>March 12, 2008</study_first_submitted>
  <study_first_submitted_qc>March 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2008</study_first_posted>
  <results_first_submitted>August 17, 2011</results_first_submitted>
  <results_first_submitted_qc>July 10, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">August 7, 2018</results_first_posted>
  <last_update_submitted>July 10, 2018</last_update_submitted>
  <last_update_submitted_qc>July 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Maimonides Medical Center</investigator_affiliation>
    <investigator_full_name>kalpana tyagaraj</investigator_full_name>
    <investigator_title>Attending, Anesthesiology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Ketorolac Tromethamine</mesh_term>
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ketorolac</title>
          <description>Patients will receive Ketorolac at 5 mg/hr not to exceed 120 mg/day</description>
        </group>
        <group group_id="P2">
          <title>Ketorolac With Rpopivacaine</title>
          <description>Patients will receive Ketorolac 5 mg and Ropivacaine 0.5% via an infusion catheter at the incision siteKetorolac and Ropivacaine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Overall number of participants: 35 in Ketorolac group and 32 in Ketorolac with Ropivacaine group.
Number of participants analyzed: 30 in each group. 5 participants from the ketorolac and 2 participants from the Ketorolac with Ropivacaine group were omitted from the study.
Reason for omission- Physician decision.</population>
      <group_list>
        <group group_id="B1">
          <title>Ketorolac</title>
          <description>Patients will receive Ketorolac at 5 mg/hr not to exceed 120 mg/day</description>
        </group>
        <group group_id="B2">
          <title>Ketorolac With Ropivacaine</title>
          <description>Patients will receive Ketorolac and Ropivacaine 0.5% via an infusion catheter at the incision site.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>Overall number of participants: 35 in Ketorolac group and 32 in Ketorolac with Ropivacaine group.
Number of participants analyzed: 30 in each group. 5 participants from the ketorolac and 2 participants from the Ketorolac with Ropivacaine group were omitted from the study.
Reason for omission- Physician decision.</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25" lower_limit="18" upper_limit="45"/>
                    <measurement group_id="B2" value="25" lower_limit="18" upper_limit="45"/>
                    <measurement group_id="B3" value="25" lower_limit="18" upper_limit="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>Overall number of participants: 35 in Ketorolac group and 32 in Ketorolac with Ropivacaine group.
Number of participants analyzed: 30 in each group. 5 participants from the ketorolac and 2 participants from the Ketorolac with Ropivacaine group were omitted from the study.
Reason for omission- Physician decision.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <population>Overall number of participants: 35 in Ketorolac group and 32 in Ketorolac with Ropivacaine group.
Number of participants analyzed: 30 in each group. 5 participants from the ketorolac and 2 participants from the Ketorolac with Ropivacaine group were omitted from the study.
Reason for omission- Physician decision.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pain score</title>
          <description>Patients report pain scores using Visual Analog Scale (VAS) . This scale measures the severity of pain and ranges from from 1-10, &quot;1&quot; being minimal pain intensity and &quot;10&quot; being maximal pain intensity.</description>
          <population>Overall number of participants: 35 in Ketorolac group and 32 in Ketorolac with Ropivacaine group.
Number of participants analyzed: 30 in each group. 5 participants from the ketorolac and 2 participants from the Ketorolac with Ropivacaine group were omitted from the study.
Reason for omission- Physician decision.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.7" spread="2.2"/>
                    <measurement group_id="B2" value="6.2" spread="2.9"/>
                    <measurement group_id="B3" value="6.40" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Rescue analgesia utilization</title>
          <description>Data is obtained regarding use of additional pain medications for breakthrough pain like morphine and acetaminophen with codeine. Rescue analgesics are converted to morphine equivalents and reported in milligrams.</description>
          <population>Overall number of participants: 35 in Ketorolac group and 32 in Ketorolac with Ropivacaine group.
Number of participants analyzed: 30 in each group. 5 participants from the ketorolac and 2 participants from the Ketorolac with Ropivacaine group were omitted from the study.
Reason for omission- Physician decision.</population>
          <units>milligrams</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.3" spread="1.9"/>
                    <measurement group_id="B2" value="4.0" spread="2.9"/>
                    <measurement group_id="B3" value="5.2" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>Age of the participating patients, reported in years.</description>
          <population>Overall number of participants: 35 in Ketorolac group and 32 in Ketorolac with Ropivacaine group.
Number of participants analyzed: 30 in each group. 5 participants from the ketorolac and 2 participants from the Ketorolac with Ropivacaine group were omitted from the study.
Reason for omission- Physician decision.</population>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27" lower_limit="18" upper_limit="45"/>
                    <measurement group_id="B2" value="26" lower_limit="18" upper_limit="45"/>
                    <measurement group_id="B3" value="27" lower_limit="18" upper_limit="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pain Scores at Rest</title>
        <description>Patients report pain scores at rest using Visual Analog Scale (VAS). This scale measures the severity of pain and ranges from from 1-10, &quot;1&quot; being minimal pain intensity and &quot;10&quot; being maximal pain intensity.</description>
        <time_frame>1 hour after the surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketorolac</title>
            <description>Patients will receive Ketorolac at 5 mg/hr not to exceed 120 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Ketorolac With Ropivacaine</title>
            <description>Patients will receive Ketorolac and Ropivacaine 0.5% via an infusion catheter at the incision site</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Scores at Rest</title>
          <description>Patients report pain scores at rest using Visual Analog Scale (VAS). This scale measures the severity of pain and ranges from from 1-10, &quot;1&quot; being minimal pain intensity and &quot;10&quot; being maximal pain intensity.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" spread="2.2"/>
                    <measurement group_id="O2" value="6.2" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pain Score at Rest</title>
        <description>Patients report pain scores at rest using Visual Analog Scale (VAS). This scale measures the severity of pain and ranges from 1-10, &quot;1&quot; being minimal pain intensity and &quot;10&quot; being maximal pain intensity.</description>
        <time_frame>At the end of 6 hours after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketorolac</title>
            <description>Patients will receive Ketorolac at 5 mg/hr not to exceed 120 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Ketorolac With Ropivacaine</title>
            <description>Patients will receive Ketorolac and Ropivacaine 0.5% via an infusion catheter at the incision site</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Score at Rest</title>
          <description>Patients report pain scores at rest using Visual Analog Scale (VAS). This scale measures the severity of pain and ranges from 1-10, &quot;1&quot; being minimal pain intensity and &quot;10&quot; being maximal pain intensity.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="2.3"/>
                    <measurement group_id="O2" value="4.4" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pain Scores at Rest</title>
        <description>Pain scores at rest were measured using the Visual Analog Scale (VAS) at the end of 48 hours. This scale measures the severity of pain and ranges from 1-10, &quot;1&quot; being minimal pain intensity and &quot;10&quot; being maximal pain intensity.</description>
        <time_frame>48 hours after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketorolac</title>
            <description>Patients will receive Ketorolac at 5 mg/hr not to exceed 120 mg/day
Ketorolac: Patients will receive Ketorolac at 5 mg/hr not to exceed 120 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Ketorolac With Ropivacaine</title>
            <description>Patients will receive Ketorolac 5 mg/hour and Ropivacaine 0.5% via an infusion catheter at the incision site</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Scores at Rest</title>
          <description>Pain scores at rest were measured using the Visual Analog Scale (VAS) at the end of 48 hours. This scale measures the severity of pain and ranges from 1-10, &quot;1&quot; being minimal pain intensity and &quot;10&quot; being maximal pain intensity.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="1.6"/>
                    <measurement group_id="O2" value="1.6" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pain Score on Coughing</title>
        <description>Pain scores on coughing were measured using the Visual Analog Scale (VAS) at the end of 48 hours. This scale measures the severity of pain and ranges from 1-10, &quot;1&quot; being minimal pain intensity and &quot;10&quot; being maximal pain intensity.</description>
        <time_frame>1 hour after the surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketorolac</title>
            <description>Patients will receive Ketorolac at 5 mg/hr not to exceed 120 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Ketorolac With Ropivacaine</title>
            <description>Patients will receive Ketorolac and Ropivacaine 0.5% (Group 2) via an infusion catheter at the incision site</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Score on Coughing</title>
          <description>Pain scores on coughing were measured using the Visual Analog Scale (VAS) at the end of 48 hours. This scale measures the severity of pain and ranges from 1-10, &quot;1&quot; being minimal pain intensity and &quot;10&quot; being maximal pain intensity.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6" spread="2.2"/>
                    <measurement group_id="O2" value="7.5" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pain Scores on Coughing</title>
        <description>Pain scores on coughing were measured using the Visual Analog Scale (VAS) at the end of 6 hours after surgery. This scale measures the severity of pain and ranges from 1-10, &quot;1&quot; being minimal pain intensity and &quot;10&quot; being maximal pain intensity.</description>
        <time_frame>6 hours after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketorolac</title>
            <description>Patients will receive Ketorolac at 5 mg/hr not to exceed 120 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Ketorolac With Ropivacaine</title>
            <description>Patients will receive Ketorolac and Ropivacaine 0.5% via an infusion catheter at the incision site</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Scores on Coughing</title>
          <description>Pain scores on coughing were measured using the Visual Analog Scale (VAS) at the end of 6 hours after surgery. This scale measures the severity of pain and ranges from 1-10, &quot;1&quot; being minimal pain intensity and &quot;10&quot; being maximal pain intensity.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" spread="2.5"/>
                    <measurement group_id="O2" value="6.2" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pain Scores on Coughing</title>
        <description>Pain scores on coughing were measured using the Visual Analog Scale (VAS). This scale measures the severity of pain and ranges from 1-10, &quot;1&quot; being minimal pain intensity and &quot;10&quot; being maximal pain intensity.</description>
        <time_frame>48 hours after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketorolac</title>
            <description>Patients will receive Ketorolac at 5 mg/hr not to exceed 120 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Ketorolac With Ropivacaine</title>
            <description>Patients will receive Ketorolac and Ropivacaine 0.5% via an infusion catheter at the incision site</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Scores on Coughing</title>
          <description>Pain scores on coughing were measured using the Visual Analog Scale (VAS). This scale measures the severity of pain and ranges from 1-10, &quot;1&quot; being minimal pain intensity and &quot;10&quot; being maximal pain intensity.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="2.7"/>
                    <measurement group_id="O2" value="2.8" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pain on Movement</title>
        <description>Pain scores on movement was assessed using the Visual Analog Scale (VAS). This scale measures the severity of pain and ranges from 1-10, &quot;1&quot; being minimal pain intensity and &quot;10&quot; being maximal pain intensity.</description>
        <time_frame>1 hour after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketorolac</title>
            <description>Patients will receive Ketorolac at 5 mg/hr not to exceed 120 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Ketorolac With Ropivacaine</title>
            <description>Patients will receive Ketorolac and Ropivacaine 0.5% via an infusion catheter at the incision site</description>
          </group>
        </group_list>
        <measure>
          <title>Pain on Movement</title>
          <description>Pain scores on movement was assessed using the Visual Analog Scale (VAS). This scale measures the severity of pain and ranges from 1-10, &quot;1&quot; being minimal pain intensity and &quot;10&quot; being maximal pain intensity.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7" spread="1.9"/>
                    <measurement group_id="O2" value="7.3" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pain Scores on Movement</title>
        <description>Pain scores on movement were assessed using the Visual Analog Scale (VAS) at the end of 6 hours. This scale measures the severity of pain and ranges from 1-10, &quot;1&quot; being minimal pain intensity and &quot;10&quot; being maximal pain intensity.</description>
        <time_frame>6 hours after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketorolac</title>
            <description>Patients will receive Ketorolac at 5 mg/hr not to exceed 120 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Ketorolac With Ropivacaine</title>
            <description>Patients will receive Ketorolac and Ropivacaine 0.5% (Group 2) via an infusion catheter at the incision site</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Scores on Movement</title>
          <description>Pain scores on movement were assessed using the Visual Analog Scale (VAS) at the end of 6 hours. This scale measures the severity of pain and ranges from 1-10, &quot;1&quot; being minimal pain intensity and &quot;10&quot; being maximal pain intensity.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" spread="2.3"/>
                    <measurement group_id="O2" value="26.2" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pain on Movement</title>
        <description>Pain scores on movement were measured 48 hours after surgery using the Visual Analog Scale (VAS). This scale measures the severity of pain and ranges from 1-10, &quot;1&quot; being minimal pain intensity and &quot;10&quot; being maximal pain intensity.</description>
        <time_frame>48 hours afetr surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketorolac</title>
            <description>Patients will receive Ketorolac at 5 mg/hr not to exceed 120 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Ketorolac With Ropivacaine</title>
            <description>Patients will receive Ketorolac and Ropivacaine 0.5% via an infusion catheter at the incision site</description>
          </group>
        </group_list>
        <measure>
          <title>Pain on Movement</title>
          <description>Pain scores on movement were measured 48 hours after surgery using the Visual Analog Scale (VAS). This scale measures the severity of pain and ranges from 1-10, &quot;1&quot; being minimal pain intensity and &quot;10&quot; being maximal pain intensity.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" spread="2.5"/>
                    <measurement group_id="O2" value="2.5" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Morphine Equivalents Utilization</title>
        <description>Utilization of morphine and morpine equivalents for rescue analgesia was reviewed and calculated in milligrams.</description>
        <time_frame>1 hour after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketorolac</title>
            <description>Patients will receive Ketorolac at 5 mg/hr not to exceed 120 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Ketorolac With Ropivacaine</title>
            <description>Patients will receive Ketorolac and Ropivacaine 0.5% via an infusion catheter at the incision site.</description>
          </group>
        </group_list>
        <measure>
          <title>Morphine Equivalents Utilization</title>
          <description>Utilization of morphine and morpine equivalents for rescue analgesia was reviewed and calculated in milligrams.</description>
          <units>miliigrams</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" spread="1.9"/>
                    <measurement group_id="O2" value="4" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Morphine Equivalents</title>
        <description>Utilization of morphine and morphine equivalents for rescue analgesia was reviewed and calculated in milligrams.</description>
        <time_frame>12 hours after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketorolac</title>
            <description>Patients will receive Ketorolac at 5 mg/hr not to exceed 120 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Ketorolac With Ropivacaine</title>
            <description>Patients will receive Ketorolac and Ropivacaine 0.5% via an infusion catheter at the incision site</description>
          </group>
        </group_list>
        <measure>
          <title>Morphine Equivalents</title>
          <description>Utilization of morphine and morphine equivalents for rescue analgesia was reviewed and calculated in milligrams.</description>
          <units>milligrams</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="1.4"/>
                    <measurement group_id="O2" value="1.5" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Morphine Equivalents</title>
        <description>Utilization of morphine and morphine equivalents for rescue analgesia, was reviewed and calculated in milligrams.</description>
        <time_frame>48 hours afetr surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketorolac</title>
            <description>Patients will receive Ketorolac at 5 mg/hr not to exceed 120 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Ketorolac With Ropivacaine</title>
            <description>Patients will receive Ketorolac and Ropivacaine 0.5% (Group 2) via an infusion catheter at the incision site</description>
          </group>
        </group_list>
        <measure>
          <title>Morphine Equivalents</title>
          <description>Utilization of morphine and morphine equivalents for rescue analgesia, was reviewed and calculated in milligrams.</description>
          <units>milligrams</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="2.5"/>
                    <measurement group_id="O2" value="4.6" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DROWSINESS</title>
        <description>The severity of drowsiness was measured using Visual Analog Scale (VAS). The VAS scale ranges from 1-10, &quot;1&quot; meaning minimally drowsy and &quot;10&quot; meaning maximally drowsy.</description>
        <time_frame>1 hour after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketorolac</title>
            <description>Patients will receive Ketorolac at 5 mg/hr not to exceed 120 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Ketorolac With Ropivacaine</title>
            <description>Patients will receive Ketorolac and Ropivacaine 0.5% via an infusion catheter at the incision site</description>
          </group>
        </group_list>
        <measure>
          <title>DROWSINESS</title>
          <description>The severity of drowsiness was measured using Visual Analog Scale (VAS). The VAS scale ranges from 1-10, &quot;1&quot; meaning minimally drowsy and &quot;10&quot; meaning maximally drowsy.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" spread="2.7"/>
                    <measurement group_id="O2" value="4.4" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DROWSINESS</title>
        <description>The severity of drowsiness was measured using Visual Analog Scale (VAS). The VAS scale ranges from 1-10, &quot;1&quot; meaning minimally drowsy and &quot;10&quot; meaning maximally drowsy.</description>
        <time_frame>48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketorolac</title>
            <description>Patients will receive Ketorolac at 5 mg/hr not to exceed 120 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Ketorolac With Ropivacaine</title>
            <description>Patients will receive Ketorolac and Ropivacaine 0.5% via an infusion catheter at the incision site</description>
          </group>
        </group_list>
        <measure>
          <title>DROWSINESS</title>
          <description>The severity of drowsiness was measured using Visual Analog Scale (VAS). The VAS scale ranges from 1-10, &quot;1&quot; meaning minimally drowsy and &quot;10&quot; meaning maximally drowsy.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="1.7"/>
                    <measurement group_id="O2" value="0.1" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>NAUSEA</title>
        <description>The severity of nausea was measured using Visual Analog Scale (VAS). The VAS scale ranges from 1-10, &quot;1&quot; meaning minimally nauseous and &quot;10&quot; meaning maximally nauseous.</description>
        <time_frame>1 hour after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketorolac</title>
            <description>Patients will receive Ketorolac at 5 mg/hr not to exceed 120 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Ketorolac With Ropivacaine</title>
            <description>Patients will receive Ketorolac and Ropivacaine 0.5% via an infusion catheter at the incision site</description>
          </group>
        </group_list>
        <measure>
          <title>NAUSEA</title>
          <description>The severity of nausea was measured using Visual Analog Scale (VAS). The VAS scale ranges from 1-10, &quot;1&quot; meaning minimally nauseous and &quot;10&quot; meaning maximally nauseous.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="1.6"/>
                    <measurement group_id="O2" value="0.9" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>NAUSEA</title>
        <description>The severity of nausea was measured using Visual Analog Scale (VAS). The VAS scale ranges from 1-10, &quot;1&quot; meaning minimally nauseous and &quot;10&quot; meaning maximally nauseous.</description>
        <time_frame>48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketorolac</title>
            <description>Patients will receive Ketorolac at 5 mg/hr not to exceed 120 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Ketorolac With Ropivacaine</title>
            <description>Patients will receive Ketorolac and Ropivacaine 0.5% (Group 2) via an infusion catheter at the incision site</description>
          </group>
        </group_list>
        <measure>
          <title>NAUSEA</title>
          <description>The severity of nausea was measured using Visual Analog Scale (VAS). The VAS scale ranges from 1-10, &quot;1&quot; meaning minimally nauseous and &quot;10&quot; meaning maximally nauseous.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.9"/>
                    <measurement group_id="O2" value="0.4" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>VOMITING</title>
        <description>Data on number of episodes of vomiting was obtained, 6 hours after the surgery. The number of episodes were reported in numerical values, the lower numbers indicating fewer episodes and the higher numbers indicating more number of episodes of vomiting.</description>
        <time_frame>6 hours after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketorolac</title>
            <description>Patients will receive Ketorolac at 5 mg/hr not to exceed 120 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Ketorolac With Ropivacaine</title>
            <description>Patients will receive Ketorolac and Ropivacaine 0.5% (Group 2) via an infusion catheter at the incision site</description>
          </group>
        </group_list>
        <measure>
          <title>VOMITING</title>
          <description>Data on number of episodes of vomiting was obtained, 6 hours after the surgery. The number of episodes were reported in numerical values, the lower numbers indicating fewer episodes and the higher numbers indicating more number of episodes of vomiting.</description>
          <units>EPISODES</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.6"/>
                    <measurement group_id="O2" value="0.1" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>VOMITING</title>
        <description>Data on number of episodes of vomiting was obtained, 12 hours after the surgery. The number of episodes were reported in numerical values, the lower numbers indicating fewer episodes and the higher numbers indicating more number of episodes of vomiting.</description>
        <time_frame>12 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketorolac</title>
            <description>Patients will receive Ketorolac at 5 mg/hr not to exceed 120 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Ketorolac With Ropivacaine</title>
            <description>Patients will receive Ketorolac and Ropivacaine 0.5% via an infusion catheter at the incision site</description>
          </group>
        </group_list>
        <measure>
          <title>VOMITING</title>
          <description>Data on number of episodes of vomiting was obtained, 12 hours after the surgery. The number of episodes were reported in numerical values, the lower numbers indicating fewer episodes and the higher numbers indicating more number of episodes of vomiting.</description>
          <units>EPISODES</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PATIENT SATISFACTION</title>
        <description>Patient's overall satisfaction was measured using Visual Analog Scale (VAS). This scale ranges from 1-10, &quot;1&quot; indicating least satisfied and &quot;10&quot; indication very well satisfied.</description>
        <time_frame>1 hour after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketorolac</title>
            <description>Patients will receive Ketorolac at 5 mg/hr not to exceed 120 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Ketorolac With Ropivacaine</title>
            <description>Patients will receive Ketorolac and Ropivacaine 0.5% via an infusion catheter at the incision site</description>
          </group>
        </group_list>
        <measure>
          <title>PATIENT SATISFACTION</title>
          <description>Patient's overall satisfaction was measured using Visual Analog Scale (VAS). This scale ranges from 1-10, &quot;1&quot; indicating least satisfied and &quot;10&quot; indication very well satisfied.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" spread="2.6"/>
                    <measurement group_id="O2" value="4.9" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PATIENT SATISFACTION</title>
        <description>Patient's overall satisfaction was measured using Visual Analog Scale (VAS). This scale ranges from 1-10, &quot;1&quot; indicating least satisfied and &quot;10&quot; indication very well satisfied.</description>
        <time_frame>48 hours afetr surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketorolac</title>
            <description>Patients will receive Ketorolac at 5 mg/hr not to exceed 120 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Ketorolac With Ropivacaine</title>
            <description>Patients will receive Ketorolac and Ropivacaine 0.5% via an infusion catheter at the incision site</description>
          </group>
        </group_list>
        <measure>
          <title>PATIENT SATISFACTION</title>
          <description>Patient's overall satisfaction was measured using Visual Analog Scale (VAS). This scale ranges from 1-10, &quot;1&quot; indicating least satisfied and &quot;10&quot; indication very well satisfied.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" spread="1.4"/>
                    <measurement group_id="O2" value="8.5" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>one year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ketorolac</title>
          <description>Patients will receive Ketorolac at 5 mg/hr not to exceed 120 mg/day</description>
        </group>
        <group group_id="E2">
          <title>Ketorolac and Ropivacainr</title>
          <description>Patients will receive Ketorolac and Ropivacaine 0.5% via an infusion catheter at the incision site.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kalpana Tyagaraj, M.D.</name_or_title>
      <organization>Maimonides Medical Center</organization>
      <phone>718-283-9162</phone>
      <email>Kalpana_tyagaraj@msn.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

